Kyverna Therapeutics, Inc. Common Stock KYTX Open Kyverna Therapeutics, Inc. Common Stock in new tab
Kyverna Therapeutics, Inc. Common Stock Analysis (KYTX)
Is Kyverna Therapeutics, Inc. Common Stock a good investment? Kyverna Therapeutics, Inc. Common Stock (KYTX) is currently trading at 8.55 USD. Market analysts have a consensus price target of 29.60 USD. This suggests a potential upside from current levels.
Earnings Schedule: Kyverna Therapeutics, Inc. Common Stock is expected to release its next earnings report on Aug. 18, 2026. The market consensus estimate for Forward EPS is -2.78.
Investor FAQ
Does Kyverna Therapeutics, Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is Kyverna Therapeutics, Inc. Common Stock?
Kyverna Therapeutics, Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 18, 2026. The company currently has a trailing EPS of -2.89.
Company Profile
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Dividends
Historical Split Corporate Actions
Explore Premium Features
Unlock detailed news and exclusive insights with our Premium subscription.
See Pricing Plans
Community Discussion